EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Plant-Produced Broadly Neutralizing Influenza Monoclonal Antibody CR9114 Exhibits Activity Against Heterologous Avian Influenza Viruses

Janejira Jaratsittisin iD, Win Win Aung, Kaewta Rattanapisit, Pipob Suwanchaikasem, Wayu Matphong, Kanjana Srisutthisamphan, Nanchaya Wanasen, Samaporn Teeravechyan, Waranyoo Phoolcharoen iD

Vaccines · 28.02.2026 · 14 (3) · 222

DOI: 10.3390/vaccines14030222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 28.02.2026. Verfasst von Janejira Jaratsittisin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok 10330, Thailand. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chulalongkorn University, Thailand Science and Research Innovation Fund Chulalongkorn University, Second Century Fund (C2F), Chulalongkorn University, Thailand Science and Research Innovation Fund Chulalongkorn University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The continual emergence of antigenically drifted avian influenza viruses poses a persistent threat to global health and underscores the need for broadly protective approaches. Stem-directed monoclonal antibodies targeting conserved hemagglutinin (HA) epitopes are a promising strategy to address viral diversity. CR9114 is a broadly neutralizing antibody previously reported to recognize a conserved HA stem region across influenza A and B viruses.

Methods

CR9114 was transiently expressed in Nicotiana benthamiana and characterized for protein integrity, assembly, and glycosylation. Binding to recombinant hemagglutinin was assessed, and neutralizing activity was evaluated against antigenically distinct avian influenza A viruses using in vitro neutralization assays.

Results

Plant-produced CR9114 was correctly assembled as a human IgG1 κ antibody and displayed a high-mannose glycosylation profile. The antibody showed strong binding to recombinant H5 hemagglutinin (Kd = 0.15 µg/mL) and potently neutralized recent avian influenza isolates, namely A/Jiangsu/NJ210/2023 (H5N1; NT50 = 1589) and A/Gansu/23277/2019 (H7N9; NT50 = 177), demonstrating cross-subtype neutralization despite known glycan-associated constraints in Group 2 viruses.

Conclusions

These findings demonstrate that N. benthamiana is a viable platform for the rapid production of functional broadly neutralizing anti-influenza antibodies. The preserved activity of plant-produced CR9114 against contemporary avian influenza strains supports its continued evaluation as a broadly protective therapeutic candidate and highlights the potential of plant molecular pharming approaches to contribute to pandemic preparedness.

Schlagwörter

Stichwörter der Autor:innen

Nicotiana benthamianaavian influenzamonoclonal antibodyuniversal influenza

Autor:innen und Institutionen

  • Center of Excellence in Plant-produced Pharmaceuticals, Chulalongkorn University, Bangkok 10330, Thailand.
  • Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
  • Baiya Phytopharm Co., Ltd., Bangkok 10330, Thailand.
  • Virology and Vaccine Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani 12120, Thailand.

ORCID-Profile: Janejira Jaratsittisin, Waranyoo Phoolcharoen

Förderung

  • Chulalongkorn University, Thailand Science and Research Innovation Fund Chulalongkorn University
  • Second Century Fund (C2F), Chulalongkorn University
  • Thailand Science and Research Innovation Fund Chulalongkorn University
  • National Vaccine Institute

Zitieren

APA

Jaratsittisin, J., Aung, W. W., Rattanapisit, K., Suwanchaikasem, P., Matphong, W., Srisutthisamphan, K., Wanasen, N., Teeravechyan, S., & Phoolcharoen, W. (2026). Plant-Produced Broadly Neutralizing Influenza Monoclonal Antibody CR9114 Exhibits Activity Against Heterologous Avian Influenza Viruses. Vaccines, 14(3), 222. https://doi.org/10.3390/vaccines14030222

Vancouver

Jaratsittisin J, Aung WW, Rattanapisit K, Suwanchaikasem P, Matphong W, Srisutthisamphan K, et al. Plant-Produced Broadly Neutralizing Influenza Monoclonal Antibody CR9114 Exhibits Activity Against Heterologous Avian Influenza Viruses. Vaccines. 2026;14(3):222. doi:10.3390/vaccines14030222

BibTeX
@article{Jaratsittisin2026,
  author = {Jaratsittisin, Janejira and Aung, Win Win and Rattanapisit, Kaewta and Suwanchaikasem, Pipob and Matphong, Wayu and Srisutthisamphan, Kanjana and Wanasen, Nanchaya and Teeravechyan, Samaporn and Phoolcharoen, Waranyoo},
  title = {Plant-Produced Broadly Neutralizing Influenza Monoclonal Antibody CR9114 Exhibits Activity Against Heterologous Avian Influenza Viruses},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {3},
  pages = {222},
  doi = {10.3390/vaccines14030222}
}
Kostenlos starten →